top of page

600 Patients treated

Early activity detected in viral and bacterial infections

Immune effects also documented in oncology

Clinical Trials


Phase II 

Phase I 

Phase II 

       HIV: Phase II to determine the dose


       Sepsis: IRIS-7 early approach to treating sepsis





       Breast and Sarcoma: early evidences in oncology 

ELYPSE (Breast Carcinoma)

Pediatric Sarcoma

       Hematopoietic Stem Cell Transplant: first proof in hematology

T Cell Depleted HSCT

       Early Combination with Anti-PD1

CITN-1203 (Provenge Support)

CITN-14 (Urothelial Carcinoma)

CYT107 has an excellent safety profile

A good clinical
tolerance explained by

  • The natural human sequence

  • An optimized glycosylation profile

  • Similarity with endogenous IL-7

  • A self regulated receptor that vanishes with overactivation

Side effects

Most common

  • Injection site reactions

Less common to rare

  • Rash grade I/II

  • Transient elevation of liver enzymes

  • Transient respiratory distress

  • Active auto-immunity is a contraindication

Close to 600 patients treated

A systematic increase in lymphocyte counts across all studies and pathologies

Screen Shot 2023-02-27 at 9.13.07 PM.png
Screen Shot 2023-02-27 at 9.13.22 PM.png
bottom of page